Business · 28/08/2025Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product MODESYO
Summary
The FDA has awarded a priority review voucher to Chimerix, Inc. for its rare pediatric disease product MODESYO (dordaviprone), approved on August 6, 2025.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →